B. Glisson

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.

W. Hong, J. Roth, S. Swisher, 1998, Seminars in oncology.

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

C. Rudin, R. Govindan, R. Salgia, 2015 .

Systemic Treatment for Incurable Recurrent and/or Metastatic Nasopharyngeal Carcinoma

B. Glisson, Ye Guo, 2010 .

The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission.

C. Mountain, M. Valdivieso, D. Carr, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.

S. Lippman, Jung Weon Lee, Hyo-Jong Lee, 2013, Journal of the National Cancer Institute.

Proliferation dependence of topoisomerase II mediated drug action.

D. Sullivan, W. Ross, B. Glisson, 1986, Biochemistry.

PI3‐kinase pathway biomarkers in oral cancer and tumor immune cells

I. Wistuba, J. Lee, J. Myers, 2018, Head & neck.

HER2 Expression in Salivary Gland Carcinomas

C. Langer, A. Colevas, P. Amrein, 2004, Clinical Cancer Research.

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.

A. Colevas, P. Amrein, R. Haddad, 2003, Oral oncology.

Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids

Philip J. Merta, M. Siciliano, W. Ross, 2004, Cancer Chemotherapy and Pharmacology.

Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.

S. Lippman, F. Khuri, W. Hong, 2000, Seminars in oncology.

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

W. Hong, R. Perez-soler, F. Fossella, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, A. Reuben, 2018, Journal of Thoracic Oncology.

Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma : Results of a matched cohort study

A. Garden, K. Ang, S. Lippman, 1997 .

Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

S. Lippman, F. Khuri, W. Hong, 1998, Seminars in oncology.

Association of activating NOTCH1 mutations in adenoid cystic carcinoma with shorter progression-free survival to systemic therapy.

J. Heymach, M. Godoy, W. William, 2017 .

Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)

F. Khuri, W. Hong, J. Roth, 2000, Cancer Gene Therapy.

Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse

I. Wistuba, Yamei Chen, J. Heymach, 2018, Tumor Biology.

Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.

M. Ratain, S. Lippman, R. Stupp, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.

D. Shin, B. Murphy, E. Cohen, 2018, Oral oncology.

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas

Edward S. Kim, J. Lee, A. Tsao, 2018, The oncologist.

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

V. Papadimitrakopoulou, H. Tran, J. Wright, 2011, Cancer.

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.

M. Kris, M. Socinski, J. Minna, 2016 .

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

C. Rudin, R. Govindan, D. Carbone, 2018, Pneumologie.

Recurrent small cell lung cancer: update.

B. Glisson, 2003, Seminars in oncology.

A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status

A. Garden, F. Khuri, V. Papadimitrakopoulou, 2004, Cancer.

Phase II trial of gefitinib in patients with incurable salivary gland cancer

J. Erasmus, M. Kies, R. Zinner, 2005 .

Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer.

S. Lippman, W. Hong, H. Libshitz, 1992, Journal of the National Cancer Institute.

Sinonasal malignancies with neuroendocrine differentiation

A. Garden, G. Clayman, D. Rosenthal, 2004, Cancer.

Investigation of PARP1 as a therapeutic target in small cell lung cancer.

J. Weinstein, K. Coombes, Jing Wang, 2012 .

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

F. Khuri, W. Hong, J. Roth, 1999, Journal of the National Cancer Institute.

Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer

Y. Oh, W. William, R. Zinner, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC)

F. Khuri, W. Hong, R. Herbst, 2000 .

Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.

D. Shin, A. Colevas, M. Posner, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma

A. Garden, S. Lippman, G. Sanguineti, 1997, Cancer.

Phase I study of paclitaxel administered by ten-day continuous infusion

S. Lippman, R. Perez-soler, J. Kurie, 1998, Investigational New Drugs.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Bene ﬁ t from Immune Checkpoint Blockade than HLA Class I Genotype in Non – Small Cell Lung Cancer

J. Roth, I. Wistuba, J. Lee, 2022 .

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

R. Ferris, N. Rizvi, B. Keam, 2020, Clinical Cancer Research.

High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome.

R. Weber, G. Fuller, Yoko Takahashi, 2020, Annals of diagnostic pathology.

The role of docetaxel in the management of squamous cell cancer of the head and neck.

B. Glisson, 2002, Oncology.

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma

S. Lippman, F. Khuri, W. Hong, 2001, Cancer.

Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.

D. Sullivan, W. Ross, R. Gupta, 1987, NCI monographs : a publication of the National Cancer Institute.

Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer

Diane D. Liu, F. Khuri, W. Hong, 2000 .

Primary chemotherapy of brain metastasis in small-cell lung cancer.

W. Murphy, B. Glisson, J. Lee, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.

R. Weber, J. Cooper, J. Ridge, 2003, Archives of otolaryngology--head & neck surgery.

Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets

P. A. Futreal, J. Aster, J. Lee, 2020, Clinical Cancer Research.

Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents.

A. Wozniak, W. Ross, B. Glisson, 1984, Cancer research.

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

R. Herbst, C. Stevens, R. Komaki, 2004, International journal of radiation oncology, biology, physics.

Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

L. Liu, W. Ross, W Ross, 1984, Cancer research.

Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.

W. Ross, R. Gupta, B. Glisson, 1986, Cancer research.

DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy.

W. Ross, B. Glisson, Warren E. Ross, 1987, Pharmacology & therapeutics.

Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.

W. Ross, R. Gupta, B. Glisson, 1986, Cancer research.

Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents.

D. Sullivan, W. Ross, K. Chow, 1987, NCI monographs : a publication of the National Cancer Institute.

Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.

B. Esmaeli, P. Nagarajan, F. Johnson, 2019, Ophthalmic plastic and reconstructive surgery.

Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma

B. Esmaeli, P. Nagarajan, R. Ferrarotto, 2018, British Journal of Ophthalmology.

Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Jason M. Johnson, R. Weber, J. Wargo, 2021, Clinical Cancer Research.

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial

J. Lee, K. Gold, W. William, 2018, Cancer.

A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck

M. Chambers, R. Weber, I. Wistuba, 2012, Clinical Cancer Research.

Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.

Diane D. Liu, S. Lippman, F. Khuri, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P h a s e I I a n d B i o logic S tudy o f I nterferon A lfa, R etinoic Acid, a nd C isplatin i n A dvanced S quamous S kin C ancer

Diane D. Liu, S. Lippman, F. Khuri, 2002 .

Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.

Dan Liu, A. Garden, K. Ang, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma

D. Carr, W. Murphy, B. Glisson, 1988, Investigational New Drugs.

Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified

J. Lee, F. Meric-Bernstam, B. Esmaeli, 2021, Cancer.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Jing Wang, I. Wistuba, J. Sage, 2019, Cancer discovery.

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

P. Robson, Jing Wang, J. Minna, 2021, Cancer cell.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

M. Kris, J. Minna, I. Wistuba, 2017, Clinical Cancer Research.

The tumor immune contexture of salivary duct carcinoma

R. Weber, J. Lee, M. Tetzlaff, 2021, Head & neck.

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

R. Herbst, B. Sabloff, K. Pisters, 2004, Lung cancer.

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

R. Weber, T. Pajak, J. Cooper, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

C. Rudin, R. Govindan, D. Carbone, 2019, Clinical Cancer Research.

Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

S. Swisher, A. Reuben, Jianhua Zhang, 2018 .

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

Jing Wang, Roman K. Thomas, I. Wistuba, 2021, Nature Communications.

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

J. Roth, S. Swisher, V. Miller, 2021, Journal for ImmunoTherapy of Cancer.

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

P. A. Futreal, X. Yi, I. Wistuba, 2018, Nature Communications.

MYB-fusions and other potential actionable targets in adenoid cystic carcinoma

R. Ferrarotto, B. Glisson, J. Heymach, 2016, Current opinion in oncology.

Small Cell Carcinoma of the Lung

B. Glisson, E. Hanrahan, 2010 .

Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.

M. Amit, Hideaki Takahashi, S. Tam, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models

S. Ang, S. Olivares, Tiejuan Mi, 2018, Oncogene.

ZD1839 (Iressa TM ) In Non-Small-Cell Lung Cancer

F. Khuri, R. Herbst, K. Pisters, 2001 .

Novel strategies for the treatment of small-cell lung carcinoma

W. William, B. Glisson, 2011, Nature Reviews Clinical Oncology.

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial

Young Uk Kim, S. H. van der Burg, Jing Wang, 2019, JAMA oncology.

Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

A. Garden, K. Ang, P. Xia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

A. Garden, C. Jones, J. Cooper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.

Jason M. Johnson, J. Lee, J. Phan, 2019, Oral oncology.

Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma

K. Tsai, R. Weber, P. Nagarajan, 2021, Cancer.

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results

Jason M. Johnson, A. Garden, J. Lee, 2020, Clinical Cancer Research.

An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center

A. Garden, R. Weber, E. Sturgis, 2013, Cancer.

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

P. Robson, Jing Wang, J. Roth, 2020, Nature Cancer.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.

S. Lippman, R. Perez-soler, F. Fossella, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor and K‐Ras mutations and resistance of lung cancer to insulin‐like growth factor 1 receptor tyrosine kinase inhibitors

Edward S. Kim, S. Lippman, W. Hong, 2012, Cancer.

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.

F. Khuri, J. Roth, J. Lee, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Michael Peyton, Li Shen, John N Weinstein, 2012, Cancer discovery.

Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms

Constance M. Johnson, B. Bekele, Adriana López, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.

D. Nyberg, R. Perez-soler, J. Kurie, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung

J. Ning, M. Hermsen, E. Hanna, 2022, Current Oncology Reports.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Pan Tong, John V Heymach, Abena B. Redwood, 2017, Cancer research.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

Ying Feng, Pan Tong, Robert J. Cardnell, 2017, Oncotarget.

Direct correlation between FRA3B expression and cigarette smoking

T. Glover, B. Glisson, C. Stein, 2002, Genes, chromosomes & cancer.

Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma

Diane D. Liu, A. Garden, S. Lippman, 2003, Cancer.

Outcomes for olfactory neuroblastoma treated with induction chemotherapy

C. Fuller, M. Kupferman, J. Phan, 2017, Head & neck.

Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses

A. Garden, M. Amit, M. Kupferman, 2021, Cancer.

Patient-Reported Outcomes, Physician-Reported Toxicities, and Treatment Outcomes in a Modern Cohort of Patients with Sinonasal Cancer Treated Using Proton Beam Therapy.

A. Garden, P. Allen, D. Rosenthal, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nasopharyngeal Carcinoma in Nonendemic Populations

J. Corry, B. Glisson, 2012 .

Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Jing Wang, J. Minna, L. Girard, 2015, Clinical Cancer Research.

Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.

Oliver Riesterer, K Kian Ang, K. Ang, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma

F. Johnson, B. Glisson, B. Saigal, 2008, Anti-cancer drugs.

Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non‐small cell lung cancer

S. Lippman, H. Libshitz, F. Fossella, 1991, Cancer.

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

G. Mills, L. Byers, P. Ng, 2014, Molecular Cancer Therapeutics.

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma

Edward S. Kim, F. Khuri, K. Pisters, 2005, Cancer.

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

S Lippman, S. Lippman, R. Perez-soler, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Management Chapter 4: Small-cell lung cancer, mesothelioma, and thymoma

W. Scott, B. Movsas, B. Glisson, 2010 .

Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?

F. Johnson, B. Glisson, 2009, Nature Reviews Clinical Oncology.

A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report.

R. Komaki, J. Cox, F. Fossella, 1998, International journal of radiation oncology, biology, physics.

Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.

J. Phan, E. Hanna, R. Ferrarotto, 2023, Oral oncology.

Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

J. Lee, F. Meric-Bernstam, D. Kaya, 2021, Advances in Therapy.

Role of induction chemotherapy for oral cavity squamous cell carcinoma

A. Gillenwater, N. Silver, J. Phan, 2021, Cancer.

277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy

J. Roth, S. Swisher, A. Tsao, 2020, Journal for ImmunoTherapy of Cancer.

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma

P. A. Futreal, X. Yi, J. Roth, 2019, Clinical Cancer Research.

Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal Antibody

S. Lippman, Ho-Yyoung Lee, Dong-Hoon Shin, 2011, Molecular Cancer Therapeutics.

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

A. Tsao, D. Gibbons, F. Fossella, 2021, JCO precision oncology.

Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

J. Wharton, N. Restifo, B. Glisson, 1994, Lymphokine and cytokine research.

Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck

R. Weber, P. Nagarajan, M. Amit, 2020, Cancer.

Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.

Benjamin Movsas, D. Ettinger, R. Komaki, 2005, International journal of radiation oncology, biology, physics.

A Randomized, Placebo‐Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum‐Based Chemotherapy as First‐Line Treatment for Extensive‐Stage Small‐Cell Lung Cancer

K. Nackaerts, R. Ramlau, L. Paz-Ares, 2017, Clinical lung cancer.

Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

J. Gu, F. Khuri, W. Hong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells.

W. Ross, B. Glisson, S. Smallwood, 1984, Biochimica et biophysica acta.

ZD1839 (Iressa) in non-small-cell lung cancer.

F. Khuri, R. Herbst, K. Pisters, 2002, Clinical lung cancer.

Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.

A. Garden, F. Khuri, J. Lee, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy.

T. Pajak, J. Cooper, J. Ensley, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and gemcitabine combined with herceptin in patients (pt) with her2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial

F. Khuri, R. Herbst, K. Pisters, 2001 .

Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)

Jason M. Johnson, R. Weber, J. Wargo, 2019, Annals of Oncology.

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

S. Lippman, F. Fossella, D. Shin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single‐arm phase II clinical trial

Edward S. Kim, S. Lippman, L. Ginsberg, 2017, Journal of the American Academy of Dermatology.

Small cell lung carcinoma: staging, imaging, and treatment considerations.

Brett W Carter, J. Erasmus, M. Truong, 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

P. Thall, F. Khuri, R. Herbst, 2001, Cancer.

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

P. Tamboli, L. Krug, H. Tran, 2006, Cancer.

Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: A case series

B. Moore, E. Sturgis, D. Shin, 2005, Head & neck.

Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin.

R. Weber, S. Lippman, A. Tsao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

A. Garden, S. Lippman, F. Khuri, 2002, Cancer.

Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.

K. Ang, S. Lippman, F. Khuri, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histone deacetylase inhibitors enhance the apoptotic activity of insulin‐like growth factor binding protein‐3 by blocking PKC‐induced IGFBP‐3 degradation

Ho-Yyoung Lee, S. Oh, Yeul-Hong Kim, 2012, International journal of cancer.

Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN).

A. Gillenwater, V. Papadimitrakopoulou, M. Kies, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response

Jing Wang, I. Wistuba, K. Rajapakshe, 2022, Journal for ImmunoTherapy of Cancer.

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

I. Wistuba, J. Lee, A. Tsao, 2020, The oncologist.

Title : Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer

Jing Wang, I. Wistuba, J. Fujimoto, 2022 .

IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.

Adam S Garden, K Kian Ang, A. Garden, 2009, International journal of radiation oncology, biology, physics.

Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck.

R. Weber, P. Nagarajan, M. Amit, 2020, European journal of cancer.

Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer.

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.

A. Garden, K. Ang, S. Lippman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Investigation : Head and Neck Cancer Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy

A. Garden, K. Ang, R. Weber, 2013 .

Radiographic retropharyngeal lymph node involvement in HPV‐associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes

A. Garden, C. Fuller, E. Sturgis, 2019, Cancer.

Etoposide-induced DNA cleavage in human leukemia cells

W. Ross, B. Glisson, S. Smallwood-Kentro, 1987, Cancer Chemotherapy and Pharmacology.

1136ONivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer

Young Uk Kim, I. Wistuba, J. Lee, 2017 .

Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors

A. Tsao, D. Shin, B. Glisson, 2004, Cancer.

A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas.

D. Mahadevan, F. Braiteh, Y. Chae, 2015 .

Squamous Carcinoma Cell Line Topoisomerase II-reactive Drugs in a Human Head and Neck Effect of Retinoic Acid on DNA Cleavage and Cytotoxicity of Updated Version

W. Hong, Hoon Kim, L. Zwelling, 2006 .

Effect of Retinoic Acid on DNA Cleavage and Cytotoxicity of Topoisomerase II-reactive Drugs in a Human Head and Neck Squamous Carcinoma Cell Line 1

W. Hong, Hoon Kim, L. Zwelling, 2006 .

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

A. Garden, K. Ang, J. Mechalakos, 2012, The Lancet. Oncology.

New Strategies in Human Papillomavirus–Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic

R. Ferrarotto, E. Massarelli, B. Glisson, 2015, Clinical Cancer Research.

Roleof Topoisomerase II in MediatingEpipodophyllotoxin-induced DMA Cleavage1

W. Ross, Leroy F. Liu, B. Glisson, 1984 .

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

F. Khuri, W. Hong, R. Perez-soler, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

F. Khuri, W. Hong, D. Shin, 2001, Clinical Cancer Research.

A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.

R. Komaki, J. Kurie, K. Pisters, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of topotecan in patients with non-small cell lung cancer

W. Hong, R. Perez-soler, M. Raber, 1993 .

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

M. Godoy, M. Kupferman, Y. Mitani, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers

J. Myers, F. Johnson, C. Nicholas, 2015, Anti-cancer drugs.

Is there still a role for induction chemotherapy in locally advanced head and neck cancer?

B. Glisson, M. Mak, 2014, Current opinion in oncology.

New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation.

M. Curran, B. Glisson, 2019, Annual review of medicine.

Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck

R. Weber, P. Nagarajan, S. Tam, 2021, Head and Neck.

Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

P. A. Futreal, X. Yi, I. Wistuba, 2019, Nature Communications.

A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.

A. Garden, K. Ang, F. Khuri, 2005, International journal of radiation oncology, biology, physics.

Insulin‐like growth factor binding protein‐3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma

Ho-Yyoung Lee, S. Oh, J. Woo, 2012, Cancer science.

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.

R. Ferris, N. Rizvi, V. Chiou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.

R. Komaki, R. Perez-soler, J. Kurie, 1998, International journal of radiation oncology, biology, physics.

Phase II trial of recombinant IFN-α2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer

F. Khuri, F. Fossella, J. S. Lee, 1998 .

Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography.

A. Garden, K. Ang, S. Lippman, 1996, International Journal of Radiation Oncology, Biology, Physics.

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma

Diane D. Liu, F. Khuri, J. Lee, 2002, Cancer.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

J. Roth, J. Lee, S. Swisher, 2018, Clinical Cancer Research.

Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy

Ehab Y Hanna, Jack Phan, David I. Rosenthal, 2015 .

Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.

A. Garden, K. Ang, R. Weber, 2010, International Journal of Radiation Oncology, Biology, Physics.

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

N. Ajami, Jing Wang, I. Wistuba, 2023, Nature Medicine.

Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.

W. Hong, R. Herbst, R. Komaki, 2009, International journal of radiation oncology, biology, physics.

Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma

W. Hong, R. Perez-soler, F. Fossella, 1998, Cancer.

Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

R. Perez-soler, M. Truong, J. Kurie, 2000, Investigational New Drugs.

A multicenter phase II study of tgDCC‐E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma

M. Hung, D. Villaret, G. Yoo, 2002, Head & neck.

Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.

F. Khuri, B. Murphy, A. Forastiere, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary chemotherapy of advanced head and neck cancer: where do we go from here?

W. Hong, B. Glisson, W. Hong, 1996, Journal of the National Cancer Institute.

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

Edward S. Kim, F. Khuri, W. Hong, 2009, American journal of clinical oncology.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

P. A. Futreal, J. Roth, I. Wistuba, 2019, Journal of Clinical Oncology.

Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma

C. Fuller, S. Roy-Chowdhuri, B. Glisson, 2021, Cancer cytopathology.

Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.

A. Garden, K. Ang, F. Khuri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)

Diane D. Liu, G. Gladish, S. Lippman, 2007 .

Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.

D. Ettinger, W. Curran, H. Choy, 2012, International journal of radiation oncology, biology, physics.

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

Thomas K. Schulz, D. Gandara, J. Moon, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

R. Kurzrock, A. Naing, D. Hong, 2016, Oncotarget.

Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC)

Edward S. Kim, S. Lippman, W. Hong, 2005 .

Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival.

Jing Wang, A. Futreal, M. Kupferman, 2015 .

ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

C. Rudin, R. Govindan, L. Byers, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Jing Wang, J. Lee, A. Futreal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century

A. Garden, K. Ang, R. Weber, 2013, Radiation oncology.

Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

D. Gandara, R. Doebele, D. Camidge, 2010 .

Gastrostomy Tube Rates Decrease by Over 50% in Patients With Nasopharyngeal Cancer Treated With Intensity Modulated Proton Therapy (IMPT): A Case–Control Study

A. Garden, E. Holliday, R. Weber, 2014 .

Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.

B. Litzenburger, J. Lee, F. Meric-Bernstam, 2015 .

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Edward S. Kim, C. Obasaju, G. Gladish, 2005, Cancer.

Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report.

F. Khuri, R. Komaki, K. Pisters, 1997, Seminars in oncology.

Resectability of Small‐Cell Lung Cancer Following Induction Chemotherapy in Patients with Limited Disease (Stage II‐IIIb)

W. Hong, J. Roth, R. Komaki, 1991, American journal of clinical oncology.

Targeting an autocrine loop in small-cell lung cancer: irrelevant target or ineffective drug?

B. Glisson, 2010, Clinical Lung Cancer.

Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN).

A. Garden, V. Papadimitrakopoulou, M. Kies, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib for advanced cutaneous squamous cell carcinoma of head and neck: Phase II trial.

R. Weber, I. Wistuba, D. Rosenthal, 2016, Journal of Clinical Oncology.

OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study

J. Roth, S. Swisher, A. Tsao, 2019, Journal of Thoracic Oncology.

A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

A. Sabichi, S. Lippman, H. Tran, 2010 .

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma

F. Fossella, G. Blumenschein, D. Karp, 2010, Cancer.

Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.

Jason M. Johnson, J. Lee, J. Myers, 2019, Journal of Clinical Oncology.

A phase II trial of ZD 1869 for advanced cutaneous squamous cell carcinoma of the head and neck

Edward S. Kim, R. Weber, A. Chalian, 2007 .

Phase I trial of imatinib mesylate (IM), cisplatin (P), and irinotecan (I) in small cell lung cancer (SCLC).

P. Tamboli, H. Tran, V. Prieto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors

R. Ferris, N. Rizvi, J. Norton, 2016 .

Head and neck tumors

E. Horwitz, R. Mehra, J. Ridge, 2003 .

Toxicities in a phase II study of accelerated high dose thoracic radiation therapy (TRT) with concurrent chemotherapy for limited small cell lung cancer (LSCLC) (RTOG 0239)

D. Ettinger, H. Choy, J. Bradley, 2007 .

Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.

B. Movsas, H. Wagner, C. Scott, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

C. Rudin, A. Chiang, T. Burns, 2017 .

O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy

R. Herbst, C. Stevens, R. Komaki, 2003 .

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

A. Garden, J. Mechalakos, Q. Zhang, 2012, The Lancet. Oncology.

Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck

A. Garden, R. Weber, J. Thariat, 2008, Cancer.

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

Edward S. Kim, F. Khuri, M. Truong, 2009, American journal of clinical oncology.

Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).

S. Lippman, A. Tsao, M. Truong, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

R. Govindan, D. Morgensztern, A. Dowlati, 2019, Pneumologie.

Abstract 5316: Check point kinase 1 (Chk1) targeting as a novel therapeutic strategy in small cell lung cancer (SCLC)

Jing Wang, L. Byers, H. Piwnica-Worms, 2015 .

Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report

A. Tsao, R. Ferrarotto, B. Glisson, 2021, Journal of Intensive Care Medicine.

Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC).

A. Sabichi, B. Bekele, L. Ginsberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact: Topic: Molecular Changes

I. Wistuba, D. Gomez, Z. Liao, 2017 .

Phase II Study of Concurrent and Adjuvant Chemotherapy with Intensity Modulated Radiation Therapy (IMRT) or Three-dimensional Conformal Radiotherapy (3D-CRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer (NPC)[RTOG 0615]: Preliminary Toxicity Report

A. Garden, J. Mechalakos, Q. Zhang, 2010 .

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 þ Tumor Lymphocyte Density, Safety, and Ef ﬁ cacy in Patients with Oropharynx Cancer: CIAO Trial Results

C. Warneke, J. Phan, Y. Elamin, 2020 .